DirectMax vs MEDVi QUAD: Which Telehealth ED Treatment Works Better? (2026)
DirectMax and MEDVi QUAD are leading multi-ingredient compounded ED treatments sharing the same triple-action base (Apomorphine + Sildenafil + Tadalafil). DirectMax delivers it as a rapid dissolve tablet from $7.45 per dose. MEDVi QUAD adds a fourth ingredient, L-Citrulline, in a sublingual liquid for faster, food-independent onset, from $114 (5-pack) / $179 (10-pack).
Our Verdict
DirectMax suits men who want proven triple-action coverage at the lowest per-dose entry price. MEDVi QUAD suits men who want the most comprehensive multi-pathway formula and fastest sublingual onset.
Side-by-Side Feature Comparison
| Feature | DirectMax | MEDVi QUAD | Winner |
|---|---|---|---|
| Formula Type | 3-in-1 (Apomorphine + Sildenafil + Tadalafil) | 4-in-1 (Apomorphine + Sildenafil + L-Citrulline + Tadalafil) | MEDVi QUAD |
| Delivery Method | Rapid dissolve tablet | Sublingual liquid (under the tongue) | MEDVi QUAD |
| Onset Time | ~15 minutes | 10–15 minutes | MEDVi QUAD |
| Duration Window | Up to 36 hours | Up to 36 hours | Tie |
| Starting Price | From $7.45/dose | $114 (5-pack) / $179 (10-pack) | DirectMax |
| Desire Pathway | Apomorphine | Apomorphine | Tie |
| Blood-Flow Booster | — | L-Citrulline | MEDVi QUAD |
| Food Interaction | Standard tablet, may be affected by meals | Sublingual, less affected by food | MEDVi QUAD |
| No-Charge If Not Approved | Not stated | Yes | MEDVi QUAD |
| Prescription Required | Yes | Yes | Tie |
Pros and Cons
DirectMax
Pros
- Lowest per-dose entry price in the multi-ingredient ED category (from $7.45/dose)
- Triple-action formula targets arousal, firmness, and duration
- Rapid dissolve tablet format for convenient, discreet use
- Fully online medical evaluation, no clinic visit required
- Discreet plain-packaging home delivery
- 300,000+ men have started the evaluation process
Cons
- Three ingredients vs four in MEDVi QUAD (no L-Citrulline blood-flow booster)
- Standard tablet format more susceptible to food timing than sublingual
- No-charge-if-not-approved policy not explicitly stated
- Individual results vary by health profile and dosage
Best For
Men who want multi-action ED coverage, addressing desire, firmness, and duration, at the lowest possible per-dose price point.
MEDVi QUAD
Pros
- Four-ingredient formula covers the most treatment pathways in one dose
- Sublingual liquid for fastest possible absorption (10–15 min)
- Less affected by meals than swallowed tablets
- Up to 36-hour response window with no strict timing pressure
- No charge if clinician does not approve the prescription
- Ongoing clinical support included in monthly plan
Cons
- Higher entry cost at $114 (5-pack) / $179 (10-pack) vs per-dose DirectMax pricing
- Monthly subscription model, less flexibility than per-dose pricing
- Liquid sublingual format not preferred by all users
- Limited independent research on the specific 4-ingredient combined formulation
Best For
Men who want the most comprehensive multi-pathway formula with the fastest sublingual onset and the least dependence on meal timing.
Frequently Asked Questions: DirectMax vs MEDVi QUAD
ED Care Guides
Compare All ED Care Providers
See the full ranked list of ed care providers side-by-side with ratings and pricing.
View All ProvidersAdvertising & Affiliate Disclosure: We may receive compensation when you click on links to partners featured on this site. Our rankings and recommendations are based on our independent research methodology and editorial standards, not on sponsorship or payment. Some links are affiliate links, which means we may earn a commission at no extra cost to you if you make a purchase.
Medical Disclaimer: The content on this site is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for medical questions, treatment decisions, or emergency care. Do not disregard professional medical advice or delay seeking it based on information found here.
Editorial Standards: Independent research · Evidence-based analysis · Transparent methodology · 2026